About
Sublingual thin film formulation, oral small molecule
Areas of Focus
Categories
Small Molecule PharmaceuticalDrug Delivery & FormulationBoston & New England
Clinical Trials (23)
View allTotal Trials
23
As Lead Sponsor
17
As Collaborator
6
Total Enrollment
2,421
By Phase
PHASE1: 6PHASE2: 5PHASE4: 2PHASE1/PHASE2: 4PHASE3: 5EARLY_PHASE1: 1
By Status
COMPLETED: 10ACTIVE_NOT_RECRUITING: 3WITHDRAWN: 3RECRUITING: 2TERMINATED: 2UNKNOWN: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline23 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06335407Collaborator
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
PHASE1Not yet recruiting
10 participants
Started: Jul 28, 2025 · Completed: Oct 29, 2025
NCT07116694Lead Sponsor
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
PHASE2Active, not recruiting
30 participants
Started: Jun 19, 2025 · Completed: Oct 31, 2025
NCT06041646Lead Sponsor
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
PHASE4Completed
23 participants
Started: Oct 12, 2023 · Completed: Apr 29, 2024
NCT05558982Collaborator
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
PHASE2Active, not recruiting
22 participants
Started: Aug 16, 2023 · Completed: Nov 30, 2027
NCT06093451Collaborator
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
PHASE4Recruiting
32 participants
Started: Jul 1, 2023 · Completed: Jul 1, 2024
Locations (1)
Headquarters
New Haven, CT, United States
Map
Loading map...